aromasil has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, PR | 1 |
| Armeanu, S; Fersis, N; Friedrich, M; Gagulic, E; Pantic, L; Relakis, K; Smyczek-Gargya, B; Wallwiener, D | 1 |
2 other study(ies) available for aromasil and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genetic Predisposition to Disease; Humans; Hyperpigmentation; Letrozole; Male; Melanosis; Neovascularization, Pathologic; Nitriles; Pregnancy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Ultraviolet Rays; Vascular Endothelial Growth Factor A | 2017 |
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Topics: Androstadienes; Angiopoietin-1; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neovascularization, Pathologic; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tamoxifen; Taxoids; Triazoles; Vascular Endothelial Growth Factor A | 2004 |